Westerkam LL, et al. - In this retrospective cohort study involving 34 candidates, researchers sought to assess the efficacy of infliximab-abda vs infliximab administration associated with the treatment of hidradenitis suppurativa. Between 2016 and 2020, patients treated with infliximab [20 comprised the infliximab treatment group (mean [SD] age, 42.2 [13.2] years; 17 women [85%])] or infliximab-abda [14 comprised the infliximab-abda treatment group (mean [SD] age, 35.5 [10.9] years; 13 women [93%])] at the dermatology clinic at the University of North Carolina at Chapel Hill were analyzed. This cohort study discovered that both infliximab and infliximab-abda administration were associated with similar and significant disease improvement as measured by the Hidradenitis Suppurativa Clinical Response. Further research is needed to determine whether infliximab-abda is a viable treatment option for hidradenitis suppurativa.